Flexion Therapeutics (NASDAQ: FLXN) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Flexion Therapeutics to related companies based on the strength of its valuation, analyst recommendations, institutional ownership, dividends, profitability, risk and earnings.
Volatility and Risk
Flexion Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Flexion Therapeutics’ rivals have a beta of 6.03, suggesting that their average stock price is 503% more volatile than the S&P 500.
This table compares Flexion Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Flexion Therapeutics||N/A||-$71.89 million||-7.26|
|Flexion Therapeutics Competitors||$284.28 million||$34.29 million||80.41|
Flexion Therapeutics’ rivals have higher revenue and earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
72.8% of Flexion Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.0% of Flexion Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Flexion Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Flexion Therapeutics Competitors||857||3201||11603||231||2.71|
Flexion Therapeutics presently has a consensus target price of $98.33, indicating a potential upside of 286.08%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.08%. Given Flexion Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Flexion Therapeutics is more favorable than its rivals.
This table compares Flexion Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Flexion Therapeutics Competitors||-5,311.13%||-218.01%||-39.32%|
Flexion Therapeutics beats its rivals on 8 of the 12 factors compared.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.